This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
By the end of 2014, Marken will have additional qualified equipment and capacity at all of its 30 locations. Marken's dedicated focus on clinical trials and new GDP enforcement guidelines has generated a significant global increase in client requests for secure, just in time temperature control of Investigational Medical Product (IMP) shipments.
"Cost pressures and the challenge of managing global durable packaging solutions are driving Pharma companies to look for solid partnerships who offer a strong, reliable network for clinical trial supplies," saidDan Bell, Marken's Vice President Regulatory Compliance and Technical Affairs. "The increased regulatory scrutiny and requirement for a GDP compliant supply chain is driving us to increase our capacity and manage a growing number of phase change temperature controlled solutions."
Marken will announce new developments in their logistics network in the coming weeks.
